Enzymatica AB: Interim report Q1/2022: Our financial targets remain in place

2022-04-28 08:30:00

Significant Significant events after the quarter
events in
Q1

  • In · In April, Enzymatica announced that its mouth spray would be
March, launched in Turkey by its partner Sanofi in 2022. The product
Enzymatica will be sold under one of Sanofi's own brands.
announced
that its
mouth spray
would be
launched in
Mexico by
its partner
Sanofi in
2022. The
product
will be
sold under
one of
Sanofi's
own brands.

Other events
during the
quarter

  • In January,
Enzymatica's
partner STADA
took over
responsibility
in Denmark,
Norway and
Finland för
marketing,
sales and
distribution av
ColdZyme.
Moving forward,
the ColdZyme
brand will be
phased out in
these three
markets and the
product will be
sold under the
ViruProtect®
brand.
  • In March,
Enzymatica was
granted a
patent in
Australia for
the cod trypsin
that is one of
the key
components in
ColdZyme. The
patent is valid
until 2036.
  • In January
2022, a
research group
at the
University of
Innsbruck,
Austria,
published an
article with
results showing
that ColdZyme®
blocks the SARS
-CoV-2 virus to
prevent it from
attaching to
human tissue.
The study was
conducted at
the initiative
of the
researchers and
was not funded
by Enzymatica.

First quarter
  • Net sales reached SEK 4.2 (17.0)
million.
  • The result for the period was SEK -18.0
million (-8.9).
  • Earnings per share, basic and diluted,

were SEK -0.12
(-0.06).

  • Cash flow from operating activities for
the period totaled SEK -10.2 (1.3) million.

"I can well understand that our low sales during the first quarter of the year could create uncertainty among shareholders or others who follow us. But for the management and the Board of Directors, nothing has changed: Our plan remains in place and the company will reach its targets for 2026. I am proud that we as a company have been strong during trying times and thanks to long-term principal owners, we have steadily been able to continue our work to build the Enzymatica of the future", said Claus Egstrand, CEO.

The full year-end report is available on: www.enzymatica.com/investors/financial-reports

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on 28 April 2022.

For more information, please contact:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 (0) 708 55 11 85 | Email: stefan.olsson@enzymatica.com
Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se. Enzymatica's Certified Adviser is Erik Penser Bank. Tel: +46 8 463 83 00 Email: certifiedadviser@penser.se.

Cision